Poging GOUD - Vrij
GSK gains hinge on new launches, base biz traction
Business Standard
|October 03, 2025
Stock may not see near-term recovery, with weak show in Indian pharma mkt
The stock of Glaxo SmithKline Pharmaceuticals or GSK Pharma has shed a fifth of its value over the last three months. The weakness in the stock is largely on account of a muted performance in the first quarter of 2025-26 (Q1FY26).
The Q1 was impacted by sluggish show of the base business and supply disruption, resulting in brokerages cutting their earnings estimates. While new launches, especially in the vaccine and specialty segments, and a recovery in the general medicines are key triggers, the stock may not see a recovery in the near term, given the growth underperformance in the Indian pharma market in recent months.
Dit verhaal komt uit de October 03, 2025-editie van Business Standard.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Business Standard
Business Standard
‘Investor awareness becomes more important than ever’
Ananth Narayan G describes his three-year tenure as whole-time member of the Securities and Exchange Board of India (Sebi) as a privilege that allowed him to make an impact on a larger canvas.
3 mins
November 01, 2025
Business Standard
New currency of hard power
If China is an exporting superpower, America is an importing one. Mr Trump has turned what would usually be a liability into an asset
5 mins
November 01, 2025
Business Standard
Apple's India revenue hits new high in Sep qtr
Apple set an all-time revenue record in India for the September quarter, driven by strong iPhone sales, as the American technology giant’s overall sales revenue reached $102.5 billion globally.
1 mins
November 01, 2025
Business Standard
USFDA's new biosimilar norms to woo more players, fast-track mkt entry
The US Food and Drug Administration’s (USEDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars — lower-priced, near-replicas of complex biologic medicines — could significantly benefit Indian biotech companies.
2 mins
November 01, 2025
Business Standard
Apple revenue tops $100 bn for first time
iPhone price hike drives record quarter
1 mins
November 01, 2025
Business Standard
Broking industry sees high growth on digital push
The Indian broking industry is passing through a lean patch after two years of rapid growth and expansion.
3 mins
November 01, 2025
Business Standard
Al-related stocks have more room to grow'
Artificial intelligence (AI)-related stocks have more room to grow, said Mark Matthews, managing director (MD) and head of research for Asia at Julius Baer during lunch on the sidelines of the Business Standard BFSI Insight Summit 2025 on Friday.
1 mins
November 01, 2025
Business Standard
'Al unlikely to replace humans in fin services'
Artificial intelligence, or AI, has had an influence in the way we invest in stocks. While it helps you narrow the list of opportunities, it has not reached a point where it can replace wealth managers, points out Shankar Sharma, founder, GQuants, in a fireside chat with A K Bhattacharya. Edited excerpts:
4 mins
November 01, 2025
Business Standard
Vedanta net profit plunges 59% on exceptional losses
Mining major Vedanta’s consolidated net profit plunged 58.69 per cent year-on-year (Y-0-Y) to %1,798 crore inthe second quarter of 2025-26 (Q2FY26), dragged down by exceptional losses booked during the period under review. The company had reported anet exceptional gain of $1,160 crore in Q2FY25.
2 mins
November 01, 2025
Business Standard
Sebi chief stresses responsible tech use, stronger market resilience
The Securities and Exchange Board of India (Sebi) is promoting the responsible use of emerging technologies, such as artificial intelligence in financial markets, strengthening cybersecurity, and preparing entities for change, said Chairman Tuhin Kanta Pandey on Friday.
1 mins
November 01, 2025
Listen
Translate
Change font size